| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.063 | 0.1 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | -0.057 | 0.1 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | TGX221 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.1 |
| mRNA | Camptothecin | GDSC1000 | pan-cancer | AAC | -0.053 | 0.1 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.084 | 0.1 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.24 | 0.1 |
| mRNA | Rapamycin | GDSC1000 | pan-cancer | AAC | 0.078 | 0.1 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | -0.053 | 0.1 |